Friday, March 5, 2021
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosurveillance

First Cases of B.1.1.7 Variant COVID-19 Detected in Washington State

by Global Biodefense Staff
January 23, 2021
Finding the Golden Window for Collecting COVID-19 Survivor Antibodies

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: NIAID

The Washington State Department of Health (DOH) along with the Snohomish Health District and the UW Medicine Virology Lab today announced the detection of B.1.1.7 variant COVID-19 for the first time in the state.

The UW Medicine Virology Lab detected two cases of the COVID-19 variant, known as B.1.1.7 or SARS-CoV-2 VOC 202012/01 in specimens collected from two Snohomish County residents. The lab screened 1,035 samples between December 25, 2020 and January 20, 2021 to detect mutations associated with B.1.1.7, first identified in the United Kingdom (UK).

The lab confirmed the variant by whole viral genome sequencing. Data collected so far suggests a low prevalence of the B.1.1.7 variant in western Washington. Although these are the first detected B.1.1.7 variants in the state, it is likely that other cases exist and will come to light through ongoing surveillance.

“We thought this variant of concern was here and now we know it’s here. It was a huge team effort by the UW Medicine Virology Lab and required development of several new rapid tests to detect and confirm it,” said Dr. Alex Greninger, Assistant Professor of the Clinical Virology Lab at UW Medicine.

“The Snohomish Health District had already instituted standard case investigation, isolation, and contact tracing prior to learning about these cases,” said Dr. Chris Spitters, Health Officer for the Snohomish Health District. “Containment protocols are no different for B.1.1.7 variants than they are for all other cases of COVID-19. Follow-up investigation is underway to learn more about these cases and the individuals who tested positive for this strain.”

The B.1.1.7 variant, first detected globally in September 2020, emerged with an unusually large number of mutations and has now spread significantly in London and southeast England. This variant spreads more easily and quickly than other variants. According to the Centers for Disease Control and Prevention (CDC), there is no conclusive evidence that it causes more severe illness or increased risk of death. In a report last week, CDC estimated that this strain will become the dominant strain in the U.S. within a few months. Data they provided show that, through January 22, there were 195 detections of this variant in 22 states.

“While finding the B.1.1.7 variant is concerning, we knew it was only a matter of time before we found evidence of it here in Washington. That said, the health and safety of all Washingtonians remains our top priority,” said Secretary of Health Umair A. Shah, MD, MPH. “Now that this variant has been found, it underscores the absolute importance of doubling down on all the prevention measures to protect Washingtonians.”

Source: Washington State Department of Health

Tags: COVID-19Editor PickEpidemiologySARS-CoV-2

Related Posts

Medical Countermeasure Development
Funding News

2021 BAA for Development of Medical Countermeasures for Biological Threats

March 2, 2021
UC San Diego Awarded NIH Funding for Rapid Acceleration of Diagnostics (RADx)
Funding News

UC San Diego Awarded NIH Funding for Rapid Acceleration of Diagnostics (RADx)

March 2, 2021
New Coronavirus Variant: Here Is What Scientists Know About B1525
Biosurveillance

New Coronavirus Variant: Here Is What Scientists Know About B1525

March 2, 2021
How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines?
Medical Countermeasures

How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines?

March 2, 2021
Load More

Latest News

Medical Countermeasure Development

2021 BAA for Development of Medical Countermeasures for Biological Threats

March 2, 2021
UC San Diego Awarded NIH Funding for Rapid Acceleration of Diagnostics (RADx)

UC San Diego Awarded NIH Funding for Rapid Acceleration of Diagnostics (RADx)

March 2, 2021
New Coronavirus Variant: Here Is What Scientists Know About B1525

New Coronavirus Variant: Here Is What Scientists Know About B1525

March 2, 2021
How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines?

How Does the Johnson & Johnson Vaccine Compare to the Other Coronavirus Vaccines?

March 2, 2021

Upcoming Events

Mar 5
Virtual Event
March 2 - March 5

Effectiveness of Non-Vaccine Influenza Control Measures

Mar 6
Virtual Event
March 6 - March 10

CROI 2021 – Conference on Retroviruses and Opportunistic Infections

Mar 8
Virtual Event
March 8 - March 10

Quantum-Enabled Sensing and Imaging for Biology

Mar 8
Virtual Event
2:00 pm - 3:30 pm

TRB Webinar: Visualizing Effects of COVID-19 on Transportation: A One-Year Retrospective

Mar 9
Virtual Event
March 9 - March 11

The Current Global Governance Landscape for Influenza

View More
Tweets by GlobalBioD

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2021 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Events
    • All Events
    • Deadlines
    • Webinar-Webcast
    • Awareness Events
  • Subscribe

© 2021 Stemar Media Group LLC